Study details
Enrolling now
CTX112 Trial
CRISPR Therapeutics AG
NCT IDNCT05643742ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
120
Study length
about 7 years
Ages
18+
Locations
4 sites in KS, MO, TX +1
About this study
This trial is testing the safety and effectiveness of CTX112 in people with relapsed or refractory B-cell malignancies. CTX112 is a type of immunotherapy that uses modified T cells to target cancer cells.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive CTX112
PhasePhase 1/Phase 2
Primary goalPhase 1 (Dose Escalation): Incidence of adverse events, defined as dose-limiting toxicities
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Phase 1 (Dose Escalation): Incidence of adverse events, defined as dose-limiting toxicities, Phase 2 (Cohort Expansion): Objective response rate
Secondary: Duration of Response, Overall Survival, Progression Free Survival
Body systems
Oncology